Comparing a fixed-cycle treatment to BTK inhibitor alone for CLL/SLL
Treatments studied
Part of Cancer clinical trials.
This study compares a fixed-cycle treatment with a BTK inhibitor (a type of targeted therapy) to see which works better for CLL/SLL. It is for people who need treatment and have not had standard therapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Your doctor says you need treatment for your CLL/SLL.
- You are able to perform daily activities (ECOG performance score 0-2).
- You have not received standard treatment for CLL/SLL before, or have had no treatment at all.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
This Phase 2 study tests whether orelabrutinib (a targeted pill) plus BG treatment works better as the first treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It may help shrink measurable lymph nodes and improve disease control in people who have not received CLL/SLL treatment before.
This trial tests two targeted drugs: zanubrutinib followed by a combination with sonrotoclax for people with newly diagnosed CLL or SLL who need treatment for the first time. The goal is to see if a limited-duration, fixed-course treatment can control the disease effectively.
This trial tests two new oral medications (ICP-248 and Orelabrutinib) together as a first treatment for people with CLL or SLL. The goal is to see if this combination works better than current options and is safe for newly diagnosed patients.
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.